Page 1

Cantargia INTERIM REPORT January - March 2021 Heading for new milestones FIRST QUARTER ● ● Net sales : SEK 0 ( 0 ) million Operating loss : SEK -73.2 ( -39.9 ) million Loss after tax : SEK -72.6 ( -40.0 ) million Loss per share : before and after dilution , SEK -0.72 ( -0.49 ) Significant events in the first quarter ● The first patient with pancreatic cancer started treatment in the extension part of the CANFOUR study An application was submitted to start a new phase lb clinical study on combination treatment with CANO4 and FOLFIRINOX in pancreatic cancer Positive preclinical safety and efficacy results were presented for the CAN10 antibody Significant events after the end of the period ● Preclinical results for the CAN 10 antibody were presented at the IMMUNOLOGY2021 conference A letter of intent was signed with GEICAM to conduct a clinical study with CANO4 in combination with carboplatin / gemcitabine in triple negative breast cancer ● Positive interim results were presented from the CANFOUR study showing an improved progression - free survival and overall survival for combination treatment with CANO4 and chemotherapy in pancreatic cancer , compared to historical control data Cantargia AB | 556791-6019 | INTERIM REPORT January - March 2021 Equity / assets ratio : 94 ( 95 ) per cent Cash and cash equivalents : SEK 176.4 ( 237.2 ) million Short - term investments : SEK 666.0 ( 259.6 ) million Comments on significant events Alongside the evaluation of CANO4 and gemcitabine / nab - paclitaxel in pancreatic cancer in CANFOUR , treatment of the first patient in an extension part of this study was started . The aim is to obtain more information on the relationship between dose , safety and efficacy . The study protocol has been simplified to shorten the time for tests before the start of treatment . Around 20-40 patients are expected to be recruited over a 6 - month period . An application for a third clinical study with CANO4 was submitted to the relevant authorities in France and Spain to further investigate the potential of CANO4 in combination with chemotherapy in pancreatic cancer . The study will include up to 30 patients and will evaluate CANO4 combination treatment with FOLFIRINOX , a chemotherapy that is one of the two most common first - line treatments for this type of cancer . The CAN 10 project progressed during the period with positive preclinical results on both safety and efficacy . In the first toxicology study with CAN10 , no toxicity was observed in single dose treatment up to 50 mg / kg and expected levels of CAN10 were measured in the blood . In a preclinical model of myocarditis , CAN10 reduced inflammation and fibrosis and also showed an ability to counteract the deterioration in cardiac function . Results from this and other preclinical models were presented at the annual conference of the American Association of Immunologists , IMMUNOLOGY2021 . Cantargia intends to broaden the development of CANO4 to cover additional cancer types . As part of this effort , a letter of intent was signed with the Spanish Breast Cancer Group ( GEICAM ) to conduct a clinical study which CANO4 will be evaluated with carboplatin / gemcitabine in patients with triple negative breast cancer . After an initial safety phase , the second part of the study will be conducted against a control group . Additional positive interim results were presented from the CANFOUR study , where treatment with CANO4 and gemcitabine / nab - paclitaxel is evaluated in pancreatic cancer patients . The results are strong compared to historical control data for chemotherapy alone . Both durable responses as well as five patients with so - called pseudoprogression , which is an unusual observation in these types of patients . Overall , this resulted in progression - free survival of 7,8 months and an overall survival of 12.6 months . PAGE 1